Essential Hypertension
Conditions
Keywords
Essential Hypertension, Remote Ischemic Conditioning
Brief summary
The purpose of this study is to explore the efficacy and safety of remote ischemic conditioning for essential hypertension in the community population.
Detailed description
At present, stroke has become the leading cause of death in China, with hypertension being the primary risk factor and one of the controllable risk factors. Current studies have shown that remote ischemic conditioning can improve vascular endothelial function, inhibit sympathetic nervous system activity and regulate immune and inflammatory reactions. Thus it may exert anti-hypertensive effects through multiple mechanisms. The purpose of this study is to investigate the efficacy and safety of remote ischemic conditioning for essential hypertension in the community population.
Interventions
DEVICEPatients are treated with previous antihypertensive treatment plus remote ischemic conditioning.
Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg.
OTHERPrevious antihypertensive treatment
Patients are only treated with previous antihypertensive treatment.
Sponsors
Yi Yang
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age≥30 years, ≤ 75 years, regardless of sex; 2. Patients with a history of essential hypertension and systolic blood pressure (SBP) ≥140 mmHg in three blood pressure measurements performed on separate days within 3 days prior to enrollment. 3. Signed and dated informed consent is obtained.
Exclusion criteria
1. Blood pressure ≥ 180/110mmHg; 2. Planned adjustment of antihypertensive drugs within the next 3 weeks; 3. Severe hematologic disorders or significant coagulation abnormalities; 4. Individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc; 5. Pregnant or lactating women; 6. Severe hepatic and renal dysfunction; 7. Patients being enrolled or having been enrolled in another clinical trial within the 3 months prior to this clinical trial; 8. Patients unsuitable for enrollment in the clinical trial according to the investigator's discretion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes of mean systolic blood pressure | 12-14 days | The mean systolic blood pressure in the last 3 days of treatment minus baseline mean systolic blood pressure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean systolic blood pressure level | 12-14 days | Mean systolic blood pressure levels during the last 3 days of treatment |
| Changes of mean diastolic blood pressure | 12-14 days | The mean diastolic blood pressure in the last 3 days of treatment minus baseline mean diastolic blood pressure |
| Mean diastolic blood pressure level | 12-14 days | Mean diastolic blood pressure levels during the last 3 days of treatment |
| Blood pressure target achievement rate | 14 days | Blood pressure target achievement rate after treatment |
Countries
China
Contacts
CONTACTYi Yang, MD,PhD
CONTACTZhen-Ni Guo, MD
Outcome results
None listed